Series: Pork Industry Research Series — Farm Animal Transparency (FAT) Published: July 29, 2026 · Author: Dirk Adams · Est. read: 9 min Revision note: First publication. This briefing relies only on federal regulations, U.S. and EU government records, and peer-reviewed or government scientific bodies. Company names are drawn from official USDA Agricultural Marketing Service (AMS) verification listings, not from press coverage.

Abstract

Ractopamine hydrochloride is a beta-adrenergic agonist feed additive approved by the U.S. Food and Drug Administration (FDA) for finishing swine. It is legal and unlabeled in conventional U.S. pork, yet major U.S. and international export markets require pork verified as produced from animals never fed the drug. That divergence has produced a federal verification system — the USDA AMS Never Fed Beta Agonists Program — whose public listings name the processors operating ractopamine-free (verified) pork lines. Those listings are the most reliable government record available of who avoids the drug in a verified way. There is, by contrast, no federal registry of who uses it, and no mandatory label disclosure of use — a transparency asymmetry that this briefing documents.

Key takeaways

• Ractopamine is FDA-approved for finishing swine (Paylean, sponsor Elanco) and requires no disclosure on the U.S. pork label when used [1][2].
• USDA AMS operates a voluntary “Never Fed Beta Agonists (Ractopamine)” verification program; its April 23, 2026 Official Listing names 26 pork operations — including Tyson Fresh Meats, Swift Pork (JBS), Smithfield, Seaboard, Triumph Foods, Hormel, and Clemens Food Group — that run verified ractopamine-free programs, largely for export to markets such as China and Russia [3][4][5].
• The European Food Safety Authority (EFSA) concluded in 2009 that the available human-safety data were insufficient to set a safe residue level, the scientific basis underlying the EU’s continued prohibition [6].
• Verified participation means a company operates a ractopamine-free program or product line — not necessarily that its entire supply is ractopamine-free. Government records do not publish company-level admissions of use.

1. Governing Legal Framework

Ractopamine hydrochloride was approved by FDA for use in finishing swine under New Animal Drug Application (NADA) 140-863, sponsored by Elanco Animal Health (then a division of Eli Lilly and Co.) and marketed as Paylean. The approval was codified in the Federal Register and appears in the Code of Federal Regulations at 21 CFR 558.500, which authorizes ractopamine as a Type A medicated article for finishing swine weighing 150–240 pounds, “fed continuously as the sole ration,” and not for use in breeding swine [1][2].

Residue limits and intake ceilings are set at 21 CFR 556.570: a tolerance of 0.05 ppm in muscle and 0.15 ppm in liver, with an acceptable daily intake (ADI) of 1.25 micrograms per kilogram of body weight per day [1]. These are the federal numbers that U.S. testing programs and export-verification audits are built around.

Nothing in the approval requires that the finished retail product disclose whether ractopamine was fed. Origin and inspection are regulated by USDA’s Food Safety and Inspection Service (FSIS); a “never fed” claim, by contrast, is voluntary and must be verified through the process described in Section 3.

2. What Ractopamine Is and What It Does

Ractopamine is a beta-adrenergic agonist — a “repartitioning agent.” Administered in feed during the finishing phase, it shifts nutrient use away from fat deposition and toward skeletal-muscle (lean) growth, improving weight-gain rate, feed efficiency, and carcass leanness. This mechanism is the stated purpose of the FDA approval, whose labeled effects for finishing swine are increased rate of weight gain, improved feed efficiency, and improved carcass leanness/quality [1][2].

Because the compound is pharmacologically active, the regulatory record also documents cautions: the approval restricts it to finishing (not breeding) animals, and international scientific bodies have focused their disagreement on the human-cardiovascular data (Section 5) [1][6].

3. The Verification System — and Why It Exists

Conventional U.S. pork may lawfully contain ractopamine and carries no statement either way. To sell into markets that prohibit the drug, U.S. processors must prove a negative — that specific animals were never fed a beta agonist. USDA AMS provides that mechanism through the Never Fed Beta Agonists Program, verified under AMS audit standards (QAD 1001 Process Verified Program / QAD 1002 Quality System Assessment, meeting QAD 1007 requirements). Verified suppliers are subject to testing for beta-agonist residues and traceability to the farm of origin [3][5].

Ractopamine is the beta agonist at issue for swine: AMS program documentation for pork states the claim explicitly as “Never Feed Beta Agonists (Ractopamine)” [5]. The program exists precisely because default U.S. pork is not verified as ractopamine-free — the government built an opt-in program to certify the exception, not the rule.

4. Who Verifies “Never Fed” — Processors on the Public Record

The USDA AMS Official Listing of the Never Fed Beta Agonists Program, last revised April 23, 2026, names the pork operations with active verified programs. These are companies with government-audited ractopamine-free lines (several facilities are approved specifically for Russian Federation and/or China trade). Named operations include [4]:

• Tyson Fresh Meats (multiple facilities)
• Swift Pork Company — the JBS pork subsidiary (multiple facilities); JBS’s Process Verified Program lists “Never Feed Beta Agonists (Ractopamine)” as a distinct verified claim [5]
• Smithfield Fresh Meats Corp. and Smithfield Packaged Meats Corp. (multiple facilities); Smithfield’s PVP verifies animals “subject to testing for beta agonist residues” under QAD 1007 [7]
• Seaboard Foods and Seaboard Triumph Foods
• Triumph Foods
• Hormel Foods Corporation
• Clemens Food Group
• Indiana Packers Corporation
• Wholestone Farms
• Premium Iowa Pork and Premium Minnesota Pork
• Quality Pork Processors and Quality Pork International
• Rantoul Foods (dba Agar Foods), Independent Meat Company, Villari Foods, The Pork Company, Kansas City Sausage Company, Eagle Grove Cooperative, Albert Lea Select Foods, and cold-storage/logistics handlers (Americold, ColdPoint, Crystal Distribution, Quality Refrigerated Services)

Critical interpretation. Appearing on this listing means the company operates a verified ractopamine-free program or product line — typically to serve export or private-label demand. It does not establish that the company’s entire U.S. output is ractopamine-free. A processor can simultaneously run a verified “never fed” line and conventional (unverified, potentially ractopamine-fed) production. The listing documents verified avoidance; it does not document company-wide practice.

5. Who Uses It — and Why the Record Is Asymmetric

The federal record clearly documents who is licensed to make and sell the drug (Elanco, via the FDA-approved NADA) and who has verified they avoid it (the AMS listing). It does not publish a corresponding registry of which farms or brands currently feed ractopamine, and U.S. labeling rules do not require disclosure of use. As a result, there is no government or peer-reviewed source that names specific hog operations “admitting” current use.

What the regulatory structure supports is an inference, not a roster: FDA approval makes ractopamine lawful in ordinary finishing swine; AMS created a dedicated “never fed” verification pathway because conventional pork is not presumed free of it; and export markets condition access on that verification. The absence of a use registry — combined with no mandatory label statement — is itself the transparency gap FAT tracks. The verified-free list is public; the used-in list does not exist in the federal record.

6. International Regulatory Divergence

The clearest government-scientific basis for the international split is EFSA’s 2009 opinion. The EFSA FEEDAP Panel concluded that “the study on cardiovascular effects in humans cannot be taken as a basis to derive an Acceptable Daily Intake” and identified “weaknesses in the data underlying the JECFA assessment which would undermine any proposal for a maximum residue level for ractopamine” [6]. On that scientific footing, the European Union has not permitted the drug, and major markets including China and the Russian Federation require ractopamine-free verification for imported U.S. pork — the demand that the AMS program in Section 4 is built to satisfy [4][6].

The disagreement is therefore not primarily about whether ractopamine works, but about whether the human-safety dataset is sufficient to set a safe residue level — a question on which the FDA (which set U.S. tolerances) and EFSA (which found the data inadequate) reached different regulatory conclusions [1][6].

7. Practical Implications

For producers. A verified “Never Fed Beta Agonists (Ractopamine)” program is an AMS-audited claim with residue testing and farm traceability — a concrete, defensible differentiator, especially for export and private-label channels [3][5].

For processors and retailers. Presence on the AMS Official Listing substantiates a ractopamine-free line; it should not be marketed as a company-wide guarantee unless the entire supply is enrolled. The verified claim and the conventional product are distinct [4].

For consumers. Conventional U.S. pork carries no statement about ractopamine either way. The only reliable signal of avoidance is a verified “never fed beta agonists / no ractopamine / raised without ractopamine” claim traceable to the AMS program — a distinction the FAT App is designed to surface at the shelf.

This briefing distinguishes ractopamine (a specific FDA-regulated beta-agonist feed additive) from dietary or carcass “fat.” Farm Animal Transparency (FAT) — farmanimaltransparency.com.

Footnotes

1. FDA, Freedom of Information Summary, NADA 140-863 (Paylean / ractopamine hydrochloride for finishing swine); residue tolerances and ADI codified at 21 CFR 556.570.
2. Federal Register, “New Animal Drugs for Use in Animal Feeds; Ractopamine Hydrochloride,” 21 CFR 558.500 (finishing swine 150–240 lb; not for breeding swine).
3. USDA Agricultural Marketing Service, “Never Fed Beta Agonists Program” (verification via QAD 1001 PVP / QAD 1002 QSA; QAD 1007 requirements; residue testing).
4. USDA AMS, “Official Listing of the Never Fed Beta Agonists Program,” last revised April 23, 2026 (named pork operations; facilities approved for Russian Federation and/or China trade).
5. USDA AMS, JBS USA / Swift Pork Company Process Verified Program (verified claim: “Never Feed Beta Agonists (Ractopamine)”).
6. EFSA, FEEDAP Panel Scientific Opinion on the safety evaluation of ractopamine (2009); EFSA news summary “EFSA evaluates safety of ractopamine in feed.”
7. USDA AMS, Smithfield Process Verified Program (pigs “subject to testing for beta agonist residues,” QAD 1007).

Additional References

• FDA — FOI Summaries, Approved New Animal Drugs (Green Book): fda.gov
• FDA Animal Drugs @ FDA — NADA 140-863 FOI Summary: animaldrugsatfda.fda.gov
• Federal Register — Ractopamine Hydrochloride (21 CFR 558.500): federalregister.gov
• USDA AMS — Never Fed Beta Agonists Program: ams.usda.gov
• USDA AMS — Official Listing, Never Fed Beta Agonists Program (PDF): ams.usda.gov (PDF)
• USDA AMS — JBS USA / Swift Pork Process Verified Program: ams.usda.gov
• USDA AMS — Smithfield Process Verified Program: ams.usda.gov
• EFSA — “EFSA evaluates safety of ractopamine in feed” (2009 FEEDAP opinion): efsa.europa.eu